Co-receptor switch during HAART is independent of virological success

Journal of Medical Virology

Volumn 81, Issue 12, 2009, Pages 2036-2044

  Saracino, Annalisa ^a   Monno, Laura ^b   Cibelli, Donatella C ^a   Punzi, Grazia ^b   Brindicci, Gaetano ^b   Ladisa, Nicoletta ^b   Tartaglia, Alessandra ^a   Lagioia, Antonella ^b   Angarano, Gioacchino ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Biological phenotype; Co receptor; env V3 loop; HIV 1

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; FOSAMPRENAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENE SWITCHING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROVIRUS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; TREATMENT OUTCOME; VIRAL TROPISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70350616458     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21598     Document Type: Article

References (45)

1. Berger EA, Murphy PM, Farber JM. 1999. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657-700.
2. Briz V, Poveda E, del Mar González M, Martín-Carbonero L, González-González R, Soriano V. 2008. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother 61:405-410.
3. Brumme ZL, Dong WWY, Yipa B, Wynhovena B, Hoffman NG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montanera JSG, Harrigan PR. 2004. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 18:F1-F9. (Pubitemid 38393456)
4. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JSG, Harrigan PR. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 192:466-474. (Pubitemid 41023125)
5. Chueca N, Garrido C, Alvarez M, Poveda E, de Dios Luna J, Zahonero N, Hernández-Quero J, Soriano V, Maroto C, de Mendoza C, García F. 2009. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatics tools. J Med Virol 81:763-767.
6. Coakley E, Benhamida J, Chappey C, Whitcomb J, Goodrich J, van der Ryst E, Westby M, James I, Tressler R, Harrigan PR, Mayer H. 2006. An evaluation of tropism profiles and other characteristics among 3988 individuals screened for the A4001026, A4001027 (MOTIVATE 1) and A4001028 (MOTIVATE 2) phase 2b/3 studies of MARAVIROC. Second International Workshop Targeting HIV Entry, Boston, MA, October 20-21, 2006 (abstract B).
7. Connor RI, Ho DD. 1994. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 68:4400-4408. (Pubitemid 24183034)
8. Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, Lail AE, Coakley EP, Gomperts ED, Donfield SM, Hemophilia Growth and Development Study. 2007. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 45:643-649. (Pubitemid 47328648)
9. de Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 66:6777-6780.
10. de Roda HAM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, Schuitemaker H. 1997. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 127:882-890. (Pubitemid 27490625)
11. Delobel P, Sandres-Sauné K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J. 2005. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38:382-392. (Pubitemid 40381547)
12. Delobel P, Nugeyre MT, Cazabat M, Sandres-Sauné K, Pasquier C, Cuzin L, Marchou B, Massip P, Cheynier R, Barré-Sinoussi F, Izopet J, Israël N. 2006. Naive T-cell depletion related to infection by X4 HIV-1 in poor immunological responders to HAART. J Virol 80:10229-10236.
13. Delobel P, Nugeyre MT, Cazabat M, Pasquier C, Marchou B, Massip P, Barre-Sinoussi F, Israël N, Izopet J. 2007. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 45:1572-1580. (Pubitemid 46762416)
14. Demarest J, Bonny T, Vavaro C, LaBranche C, Kitrinos K, McDanal C, Sparks S, Chavers S, Castillo S, Elrick D, McCarty D, Whitcomb J, Huang W, Petropoulos C, Piscitelli S. 2004. HIV-1 co-receptor tropismin treatment naive and experienced subjects. 44th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC, 30 October to 2 November 2004 (abstract H-1136).
15. Deng H, Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666. (Pubitemid 26197679)
16. Equils O, Garratty E, Wei LS, Plaeger S, Tapia M, Deville J, Krogstad P, Sim MS, Nielsen K, Bryson YJ. 2000. Recovery of replication competent virus from CD4 T cell reservoirs and change in co-receptor use in HIV-1-infected children responding to HAART. J Infect Dis 182:751-757.
17. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE1 and MOTIVATE 2 Study Teams. 2008. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359:1442-1455.
18. Fouchier RA, Brouwer M, Broersen SM, Schuitemaker H. 1995. Simple determination of human immunodeficiency virus type 1 syncytium inducing V3 genotype by PCR. J Clin Microbiol 33:906-911.
19. Galán I, Jiménez JL, González-Rivera M, De José MI, Navarro ML, Ramos JT, Mellado MJ, Gurbindo MD, Bellón JM, Resino S, Cabrero E, Muñoz-Fernández MA. 2004. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS 18:247-255.
20. Garrido C, Roulet V, Chueca N, Poveda E, Aguilera A, Skrabal K, Zahonero N, Carlos S, García F, Faudon JL, Soriano V, de Mendoza C. 2008. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 46:887-891.
21. Goodenow MM, Collman RG. 2006. HIV-1 coreceptor preference is distinct from target cell tropism:Adual-parameter nomenclature to define viral phenotypes. J Leukoc Biol 80:965-972.
22. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG, Harrigan PR. 2006. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 194:926-930. (Pubitemid 44454078)
23. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77:13376-13388.
24. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. 2003. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 77:7682-7688. (Pubitemid 36734540)
25. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. 1994. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 32:364-370. (Pubitemid 24033896)
26. Lehmann C, Däumer M, Boussaad I, Sing T, Beerenwinkel N, Lengauer T, Schmeisser N, Wyen C, Fätkenheuer G, Kaiser R. 2006. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 37:300-304. (Pubitemid 44667670)
27. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, Harrigan PR. 2007. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21:F17-F24. (Pubitemid 47329758)
28. Lwembe R, Lihana RW, Ochieng' W, Panikulam A, Mongoina CO, Palakudy T, de Koning H, Ishizaki A, Kageyama S, Musoke R, Owens M, Songok EM, Okoth FA, Ichimura H. 2009. Changes in the HIV type 1 envelope gene from non-subtype B HIV type 1-infected children in Kenya. AIDS Res Hum Retrovir 25:141-147.
29. Maas JJ, Gange SJ, Schuitemaker H, Coutinho RA, van Leeuwen R, Margolick JB. 2000. Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 14:1155-1161. (Pubitemid 30420658)
30. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 194:238-246. (Pubitemid 44087196)
31. Moore JP, Kitchen SG, Pugach P, Zack JA. 2004. The CCR5 and CXCR4 coreceptors - Central to understanding the transmission and pathogenesis of HIV-1 infection. AIDS Res Hum Retrov 20:111-126.
32. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 191:866-872. (Pubitemid 40349800)
33. Paredes R, Clotet B. 2008. HIV drug resistance testing. http://www.touchinfectionus-eu-digital.com/euinfectious/vol2iss2/template (accessed February 20, 2009).
34. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA III, Sacks HS, Mathur-Wagh U, Brunner C, Burger H. 2001. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 107:431-438. (Pubitemid 32167989)
35. Poveda E, Briz V, de Mendoza C, Benito JM, Corral A, Zahonero N, Lozano S, González-Lahoz J, Soriano V. 2007. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 79:1040-1046. (Pubitemid 47015401)
36. Poveda E, Seclén E, del Mar González M, García F, Chueca N, Aguilera A, Rodríguez JJ, González-Lahoz J, Soriano V. 2009. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 63:1006-1010.
37. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres- Sauné K, Cuzin L, Marchou B, Massip P, Izopet J. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11-F16.
38. Saracino A, Monno L, Punzi G, Cibelli DC, Tartaglia A, Scudeller L, Brindicci G, Lagioia A, Scotto G, Angarano G. 2007. HIV-1 biological phenotype and predicted co-receptor usage based on V3 loop sequence in paired PBMC and plasma samples. Virus Res 130:34-42. (Pubitemid 350051085)
39. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette M. 1991. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 65:356-363.
40. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F. 2003. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 17:809-814. (Pubitemid 36547652)
41. Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V. 2007. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. AIDS 21:2243-2250. (Pubitemid 350287224)
42. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, Winters B, Plum J, Vogelaers D, Stuyver L. 2009. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 50:126-136.
43. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. 2008. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46:1617-1623. (Pubitemid 351706746)
44. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. 2007. Development and characterization of a novel single-cycle recombinant virus assay to determine HIV-1 coreceptor tropism. Antimicrob Agents Chemother 51:566-575. (Pubitemid 46185274)
45. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. 2007. HIV type 1 chemokine coreceptor use among antiretroviral experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44:591-595. (Pubitemid 46233265)